Lamellar Biomedical, a UK-based healthcare company treating dry eyes and mouths, has raised £3.3m ($5.3m) from a consortium including peer Barwell.

Other investors included government-backed Scottish Enterprise, mutual fund manager Invesco Perpetual and angel network TRI Cap.

Tri-Cap (£260,000), Barwell (£150,000) and others had provided £935,000 to Lamellar in September 2007.

After the funding, Duncan Moore, partner at East West Capital Partners, has become chairman of Lamellar, replacing Sam Taylor from Tri-Cap.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?